Lipocine (LPCN)
(Delayed Data from NSDQ)
$4.54 USD
-0.30 (-6.20%)
Updated Sep 23, 2024 03:53 PM ET
After-Market: $4.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Lipocine Inc. [LPCN]
Reports for Purchase
Showing records 21 - 40 ( 106 total )
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Oral Testosterone for NASH Might Have Legs; Reiterate Buy Ahead of Tlando Blood Pressure Data and Potential NDA Refiling
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
3Q18 Results; Near Term Data Potentially Enables Tlando Resubmission and De-Risks 4Q19 Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Dropping Coverage due to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
We are dropping coverage of the following stocks
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Expected Tlando CRL; Negative Reaction Overdone? Reiterate Buy and $3 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
4Q Results; Expecting May Tlando CRL; Aiming for Rapid Path to Resubmission
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
FDA Shepherds AdCom to Negative Tlando Vote; Lower Target to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Transferring Coverage; Optimistic Into January Tlando AdCom; Assume With a Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Lipocine Inc.
Industry: Medical - Drugs
We are placing shares of LPCN Under Review, and transferring coverage to Scott Henry, CFA.
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
Company: Lipocine Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Lipocine Inc.
Industry: Medical - Drugs
1021 NDA Resubmission To Set Up Feb ?18 Approval Decision
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M